David Bearss

Company: Biolexis Therapeutics

Job title: President & Chief Executive Officer ,Co-Founder

Seminars:

Innovative Dual-Target Therapy for Obesity: Combining an oral GLP-1 Agonist with an oral Isoform Selective AMPK Activator` 2:40 pm

Mechanistic Synergy: BLX-7006, an oral GLP-1 agonist, promotes appetite suppression and glucose regulation, while BLX-0871, an oral isoform-selective AMPK activator, enhances skeletal muscle glucose uptake and lipid metabolism. Together, they address obesity through complementary pathways. Preclinical Evidence: Results from animal models demonstrate enhanced weight loss, improved insulin sensitivity, and significant metabolic improvements with the combined…Read more

day: Day Two